J. David Gladstone Institutes

J. David Gladstone Institutes

J. David Gladstone established these independent institutes in 1979, channeling wealth from his real estate operations into a San Francisco research center. The organization operates as a charitable biomedical foundation, not a single-family office, with a full-time president, Deepak Srivastava, directing scientific strategy. An academic affiliation with the University of California, San Francisco gives the labs access to joint faculty, but Gladstone retains its own governance and a separate endowment. Strategy blends direct translational research with venture-style placement of its intellectual property. The institutes' scientists work across cardiovascular, viral, and neurological disease, an asset-class mix that spans early-stage drug discovery, lab spinouts, and fund commitments. A co-investment venture with Dolby Family Ventures, the Cure Network Dolby Acceleration Partners, targets neurodegeneration therapies. The board includes Nicholas J. Simon, a senior managing director at Blackstone Life Sciences, linking the non-profit to commercial drug-development capital. The physical footprint is concentrated at the Owens Street headquarters in Mission Bay, while collaborations extend to UC Berkeley, LBNL, and UC Davis through the Bay Area Postdoc Coalition. The base of 188 in estimated assets (Altss estimate) supports a lean team with eight investigators holding National Academy of Medicine membership. Trustee William S. Price, III, a TPG Capital co-founder, and board member Li Lu of Himalaya Capital bring deep allocator networks to the table. An associated vehicle, the Gladstone Foundation, handles aligned philanthropic grants. The institutes' intellectual property portfolio functions as a separate value store whose realized proceeds recycle into research. Most endowed research foundations operate as grant-making pass-throughs. Gladstone instead runs its own laboratories, hires its own faculty, and monetizes discoveries directly — an operating-company posture inside a non-profit wrapper. This structure gives it both the tax-advantaged horizon of a perpetual endowment and the execution tempo of a preclinical biotech portfolio.